📰 Repeat Revascularization News
Repeat Revascularization News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Repeat Revascularization. Real-time updates on events, politics, business and more.
January 14, 2021
Marizyme Announces Approval for DuraGraft® in India Latest Approval Joins a Growing List of Countries for Commercial Sales in 2021 News provided by Share this article Share this article JUPITER, Fla., Jan. 14, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraG...
January 11, 2021
11 gennaio 2021 | 11.34 LETTURA: 5 minuti DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced as of August 2020 th...
January 11, 2021
11 gennaio 2021 11:38 Fonte: Adnkronos #salute-e-benessere DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced as of August 2020 the Vie...
January 7, 2021
Registration: https://informaconnect.com/biotech-showcase/registration-options/ During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizymes pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The companys flagship product, DuraGraft , an intra-operative vascular graft storage solution that inhibits endothelial damage, leads ...
January 7, 2021
During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizymes pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The companys flagship product, DuraGraft ®, an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications assoc...